Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Department of Radiation Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
Scand J Gastroenterol. 2020 Nov;55(11):1268-1276. doi: 10.1080/00365521.2020.1832571. Epub 2020 Oct 18.
Adenosquamous carcinoma (ASC), containing both adenocarcinoma and squamous cell carcinoma components, is rare in the digestive system. Limited data is available on ASC of the digestive system (AS-ASC), and the current evidence is available mainly in the form of case reports and case series. We performed a thorough search of the available literature and compiled a review on the epidemiology, histopathology, pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of AS-ASC. Non-specific clinical and imaging presentations and low diagnostic accuracy of biopsy lead to difficulties in preoperative diagnosis in a high proportion of patients and high malignancy. The pathogenesis remains obscure. Surgery remains the mainstay of treatment for AS-ASC. The role of chemoradiotherapy as an adjuvant treatment is still inconclusive. Key messages Metastatic linings and the lack of efficacious treatments lead to an unfavorable outcome in AS-ASC patients. Further research could help us understand the pathophysiology of AS-ASCand the unique needs of AS-ASC patients.
腺鳞癌（ASC），同时含有腺癌和鳞癌成分，在消化系统中较为罕见。消化系统的腺鳞癌（AS-ASC）的数据有限，目前的证据主要以病例报告和病例系列的形式出现。我们对现有文献进行了全面检索，并对 AS-ASC 的流行病学、组织病理学、发病机制、临床表现、诊断、治疗和预后进行了综述。非特异性的临床和影像学表现以及活检的低诊断准确性导致相当比例的患者术前诊断困难且恶性程度高。发病机制尚不清楚。手术仍然是 AS-ASC 的主要治疗方法。放化疗作为辅助治疗的作用仍不确定。关键信息 转移性衬里和缺乏有效的治疗方法导致 AS-ASC 患者的预后不佳。进一步的研究可以帮助我们了解 AS-ASC 的病理生理学和 AS-ASC 患者的独特需求。
